Overview

Adoptive Cell Therapy Following a Non-myeloablative, Lymphodepleting Induction Regimen in Metastatic Melanoma Patients

Status:
Unknown status

Trial end date:
2021-06-01

Target enrollment:

Participant gender:

Summary

Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) in combination with lymphodepletion and high-dose interleukin 2 (IL-2) has demonstrated reproducible objective response rates of approximately 50 percent in patients with highly advanced, refractory metastatic melanoma. Recent developments in theTIL ACT procedure facilitate the use of a reduced-intensity, non-myeloablative, lympho-depleting preparative regimen which is expected to be both less toxic and equally efficient compared to previous regimens.

Phase:

Phase 2

Details

Lead Sponsor:

Sheba Medical Center

Treatments:

Cyclophosphamide
Fludarabine
Fludarabine phosphate